 Jerry Stitzel
Concepts (382)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Nicotinic | 67 | 2025 | 321 | 8.820 |
Why?
| | Nicotine | 47 | 2026 | 331 | 7.910 |
Why?
| | Nicotinic Agonists | 18 | 2025 | 136 | 2.870 |
Why?
| | Tobacco Use Disorder | 19 | 2025 | 218 | 2.590 |
Why?
| | Prenatal Exposure Delayed Effects | 6 | 2026 | 675 | 1.900 |
Why?
| | Neurodevelopmental Disorders | 3 | 2026 | 227 | 1.810 |
Why?
| | Smoking | 15 | 2023 | 1472 | 1.190 |
Why?
| | Polymorphism, Single Nucleotide | 22 | 2023 | 2145 | 1.170 |
Why?
| | Brain | 22 | 2020 | 2933 | 1.090 |
Why?
| | Corpus Striatum | 6 | 2026 | 179 | 1.040 |
Why?
| | Polymorphism, Genetic | 12 | 2014 | 612 | 1.000 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 12 | 2017 | 93 | 0.990 |
Why?
| | Mice | 61 | 2026 | 18339 | 0.980 |
Why?
| | Epigenesis, Genetic | 2 | 2021 | 684 | 0.930 |
Why?
| | Receptors, Dopamine D1 | 1 | 2026 | 35 | 0.930 |
Why?
| | Mice, Inbred C3H | 15 | 2015 | 251 | 0.840 |
Why?
| | Bungarotoxins | 19 | 2014 | 45 | 0.800 |
Why?
| | Hippocampus | 10 | 2019 | 965 | 0.780 |
Why?
| | Animals | 67 | 2026 | 38058 | 0.760 |
Why?
| | Protein Subunits | 8 | 2017 | 226 | 0.760 |
Why?
| | Melatonin | 2 | 2015 | 163 | 0.740 |
Why?
| | Mice, Inbred C57BL | 23 | 2026 | 5992 | 0.740 |
Why?
| | Substance Withdrawal Syndrome | 4 | 2025 | 186 | 0.720 |
Why?
| | Nerve Tissue Proteins | 9 | 2018 | 592 | 0.670 |
Why?
| | Mice, Inbred DBA | 17 | 2015 | 187 | 0.620 |
Why?
| | Synaptosomes | 6 | 2014 | 32 | 0.610 |
Why?
| | Neurons | 4 | 2018 | 1640 | 0.600 |
Why?
| | Sleep | 5 | 2025 | 901 | 0.590 |
Why?
| | Frontal Lobe | 2 | 2019 | 160 | 0.580 |
Why?
| | Genetic Variation | 9 | 2022 | 983 | 0.580 |
Why?
| | Nicotinic Antagonists | 7 | 2017 | 35 | 0.570 |
Why?
| | Protein Precursors | 1 | 2019 | 137 | 0.570 |
Why?
| | DNA Methylation | 2 | 2021 | 681 | 0.560 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2019 | 148 | 0.560 |
Why?
| | Choice Behavior | 5 | 2015 | 177 | 0.550 |
Why?
| | Serine | 1 | 2018 | 145 | 0.540 |
Why?
| | Gene Expression Regulation | 7 | 2013 | 2608 | 0.530 |
Why?
| | Wakefulness | 1 | 2018 | 169 | 0.510 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 477 | 0.510 |
Why?
| | Species Specificity | 14 | 2012 | 574 | 0.500 |
Why?
| | Motor Activity | 12 | 2022 | 721 | 0.480 |
Why?
| | Receptors, Melatonin | 1 | 2015 | 2 | 0.450 |
Why?
| | Ethanol | 6 | 2022 | 627 | 0.450 |
Why?
| | Glucocorticoids | 1 | 2019 | 535 | 0.440 |
Why?
| | Gene Expression | 7 | 2015 | 1490 | 0.430 |
Why?
| | Sleep Wake Disorders | 1 | 2018 | 301 | 0.430 |
Why?
| | Pregnancy | 8 | 2026 | 7190 | 0.430 |
Why?
| | GABA-B Receptor Agonists | 1 | 2014 | 5 | 0.430 |
Why?
| | Sensory Gating | 1 | 2015 | 44 | 0.430 |
Why?
| | Receptors, GABA-B | 1 | 2014 | 10 | 0.430 |
Why?
| | Baclofen | 1 | 2014 | 21 | 0.420 |
Why?
| | Drinking | 3 | 2015 | 42 | 0.410 |
Why?
| | Polymorphism, Restriction Fragment Length | 7 | 2007 | 64 | 0.400 |
Why?
| | Behavior, Animal | 7 | 2019 | 519 | 0.400 |
Why?
| | Disease Models, Animal | 11 | 2026 | 4557 | 0.390 |
Why?
| | Male | 55 | 2026 | 72315 | 0.390 |
Why?
| | Schizophrenia | 4 | 2017 | 446 | 0.390 |
Why?
| | Alcohol Drinking | 5 | 2022 | 826 | 0.380 |
Why?
| | Acetylcholine | 7 | 2012 | 204 | 0.380 |
Why?
| | Female | 53 | 2026 | 78271 | 0.360 |
Why?
| | Gene Targeting | 2 | 2011 | 82 | 0.350 |
Why?
| | Calcium | 3 | 2015 | 1183 | 0.350 |
Why?
| | Mice, Inbred Strains | 10 | 2005 | 397 | 0.350 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 5 | 2018 | 279 | 0.350 |
Why?
| | Mice, Knockout | 11 | 2025 | 3121 | 0.340 |
Why?
| | Circadian Rhythm | 2 | 2015 | 514 | 0.340 |
Why?
| | Dose-Response Relationship, Drug | 12 | 2012 | 2027 | 0.340 |
Why?
| | Drug Discovery | 1 | 2011 | 155 | 0.310 |
Why?
| | Gene Knock-In Techniques | 1 | 2010 | 61 | 0.310 |
Why?
| | Administration, Oral | 4 | 2018 | 847 | 0.310 |
Why?
| | Seizures | 4 | 2007 | 460 | 0.300 |
Why?
| | Rubidium | 4 | 2002 | 11 | 0.300 |
Why?
| | Pyridines | 5 | 2018 | 605 | 0.300 |
Why?
| | Phenotype | 12 | 2023 | 3162 | 0.290 |
Why?
| | Oocytes | 1 | 2010 | 178 | 0.290 |
Why?
| | Chromosome Mapping | 2 | 2006 | 510 | 0.280 |
Why?
| | Genetic Predisposition to Disease | 8 | 2022 | 2363 | 0.280 |
Why?
| | Taste | 2 | 2015 | 239 | 0.280 |
Why?
| | Promoter Regions, Genetic | 4 | 2015 | 1257 | 0.270 |
Why?
| | Signal Transduction | 3 | 2019 | 5226 | 0.270 |
Why?
| | Brain Chemistry | 2 | 2007 | 116 | 0.270 |
Why?
| | Chlorisondamine | 1 | 2007 | 3 | 0.270 |
Why?
| | Central Nervous System Depressants | 3 | 2005 | 83 | 0.260 |
Why?
| | Genes, fos | 1 | 2007 | 37 | 0.260 |
Why?
| | Aging | 2 | 2022 | 1966 | 0.250 |
Why?
| | Corticosterone | 2 | 2019 | 244 | 0.250 |
Why?
| | Neural Inhibition | 4 | 2017 | 178 | 0.250 |
Why?
| | Mice, Transgenic | 4 | 2018 | 2182 | 0.240 |
Why?
| | Genotype | 14 | 2014 | 1833 | 0.240 |
Why?
| | Quantitative Trait Loci | 2 | 2015 | 374 | 0.230 |
Why?
| | Microsatellite Repeats | 1 | 2006 | 157 | 0.230 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 15 | 0.220 |
Why?
| | Genome-Wide Association Study | 6 | 2023 | 1406 | 0.220 |
Why?
| | Anxiety | 1 | 2012 | 1109 | 0.210 |
Why?
| | Multifactorial Inheritance | 2 | 2023 | 202 | 0.210 |
Why?
| | Up-Regulation | 2 | 2018 | 851 | 0.210 |
Why?
| | DNA-Binding Proteins | 2 | 2022 | 1499 | 0.200 |
Why?
| | Choline | 2 | 2015 | 136 | 0.200 |
Why?
| | Astrocytes | 1 | 2025 | 222 | 0.200 |
Why?
| | Maze Learning | 3 | 2012 | 103 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2025 | 436 | 0.190 |
Why?
| | Epistasis, Genetic | 1 | 2023 | 66 | 0.190 |
Why?
| | Humans | 40 | 2026 | 144759 | 0.190 |
Why?
| | Genetic Markers | 2 | 2020 | 331 | 0.180 |
Why?
| | Chronobiology Disorders | 1 | 2022 | 16 | 0.180 |
Why?
| | Tobacco Use | 1 | 2022 | 61 | 0.180 |
Why?
| | Internationality | 1 | 2022 | 156 | 0.180 |
Why?
| | Quinolizines | 3 | 2010 | 9 | 0.180 |
Why?
| | Azocines | 3 | 2010 | 8 | 0.180 |
Why?
| | Maternal Inheritance | 1 | 2021 | 15 | 0.180 |
Why?
| | Alkaloids | 3 | 2010 | 28 | 0.170 |
Why?
| | Benzazepines | 2 | 2012 | 35 | 0.170 |
Why?
| | Alternative Splicing | 1 | 2003 | 247 | 0.170 |
Why?
| | Varenicline | 2 | 2012 | 28 | 0.170 |
Why?
| | gamma-Aminobutyric Acid | 3 | 2014 | 192 | 0.170 |
Why?
| | Calcium-Binding Proteins | 1 | 2022 | 219 | 0.170 |
Why?
| | Quinoxalines | 2 | 2012 | 65 | 0.160 |
Why?
| | Muscle Proteins | 1 | 2022 | 244 | 0.160 |
Why?
| | Radioligand Assay | 3 | 2012 | 37 | 0.160 |
Why?
| | Electroencephalography | 2 | 2025 | 532 | 0.160 |
Why?
| | Histone Deacetylase 2 | 1 | 2020 | 10 | 0.160 |
Why?
| | Dopamine | 3 | 2019 | 283 | 0.160 |
Why?
| | Alzheimer Disease | 2 | 2022 | 621 | 0.160 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 1 | 2020 | 37 | 0.160 |
Why?
| | Methyl-CpG-Binding Protein 2 | 1 | 2020 | 21 | 0.150 |
Why?
| | Dioxygenases | 1 | 2020 | 36 | 0.150 |
Why?
| | Amino Acid Substitution | 3 | 2009 | 304 | 0.150 |
Why?
| | Cell Line | 6 | 2017 | 2882 | 0.150 |
Why?
| | Furin | 1 | 2019 | 13 | 0.150 |
Why?
| | Transcriptome | 2 | 2023 | 1045 | 0.150 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2019 | 26 | 0.150 |
Why?
| | Self Administration | 3 | 2025 | 124 | 0.150 |
Why?
| | Behavior, Addictive | 1 | 2020 | 88 | 0.150 |
Why?
| | Muscle, Skeletal | 1 | 2010 | 1795 | 0.150 |
Why?
| | Aequorin | 2 | 2012 | 2 | 0.150 |
Why?
| | Sexual Maturation | 1 | 2019 | 51 | 0.150 |
Why?
| | Body Temperature | 8 | 2015 | 229 | 0.150 |
Why?
| | Gene-Environment Interaction | 2 | 2018 | 180 | 0.140 |
Why?
| | Sleep, REM | 1 | 2018 | 44 | 0.140 |
Why?
| | Visual Cortex | 1 | 2019 | 84 | 0.140 |
Why?
| | Sex Factors | 3 | 2012 | 2112 | 0.130 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2018 | 381 | 0.130 |
Why?
| | Myocarditis | 1 | 2018 | 102 | 0.130 |
Why?
| | Sex Characteristics | 4 | 2025 | 790 | 0.130 |
Why?
| | Autoradiography | 3 | 2009 | 64 | 0.130 |
Why?
| | Cytochrome P-450 CYP2A6 | 1 | 2016 | 8 | 0.130 |
Why?
| | Acoustic Stimulation | 3 | 2015 | 333 | 0.130 |
Why?
| | Mutation | 4 | 2022 | 4089 | 0.120 |
Why?
| | Proto-Oncogene Proteins | 1 | 2020 | 623 | 0.120 |
Why?
| | Pyramidal Cells | 1 | 2017 | 79 | 0.120 |
Why?
| | Genetic Linkage | 1 | 1996 | 273 | 0.120 |
Why?
| | HEK293 Cells | 3 | 2015 | 744 | 0.120 |
Why?
| | Alleles | 4 | 2013 | 879 | 0.120 |
Why?
| | Cerebral Cortex | 3 | 2009 | 464 | 0.110 |
Why?
| | Substance-Related Disorders | 1 | 2005 | 1094 | 0.110 |
Why?
| | Time Factors | 6 | 2018 | 7173 | 0.110 |
Why?
| | Receptor, Melatonin, MT1 | 1 | 2015 | 6 | 0.110 |
Why?
| | Cigarette Smoking | 1 | 2016 | 99 | 0.110 |
Why?
| | Analysis of Variance | 2 | 2012 | 1306 | 0.110 |
Why?
| | Mesencephalon | 1 | 2015 | 64 | 0.110 |
Why?
| | Down Syndrome | 1 | 2022 | 534 | 0.110 |
Why?
| | Isoxazoles | 1 | 2015 | 53 | 0.110 |
Why?
| | Autoreceptors | 1 | 2014 | 4 | 0.110 |
Why?
| | Pyrethrins | 1 | 2014 | 8 | 0.110 |
Why?
| | Potassium Chloride | 1 | 2014 | 40 | 0.110 |
Why?
| | Conotoxins | 2 | 2004 | 16 | 0.110 |
Why?
| | Macrophages, Alveolar | 1 | 2017 | 368 | 0.110 |
Why?
| | Social Behavior | 1 | 2017 | 288 | 0.100 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2019 | 905 | 0.100 |
Why?
| | Phenylurea Compounds | 1 | 2015 | 112 | 0.100 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 69 | 0.100 |
Why?
| | Neurogenesis | 1 | 2015 | 156 | 0.100 |
Why?
| | Heterozygote | 1 | 2015 | 315 | 0.100 |
Why?
| | Auditory Perception | 1 | 2015 | 114 | 0.100 |
Why?
| | Mycobacterium tuberculosis | 1 | 2017 | 334 | 0.100 |
Why?
| | Crosses, Genetic | 2 | 2006 | 124 | 0.100 |
Why?
| | Base Sequence | 4 | 2013 | 2190 | 0.100 |
Why?
| | Prefrontal Cortex | 1 | 2017 | 328 | 0.100 |
Why?
| | Habituation, Psychophysiologic | 1 | 2014 | 58 | 0.100 |
Why?
| | Presynaptic Terminals | 1 | 2014 | 86 | 0.100 |
Why?
| | DNA, Intergenic | 1 | 2013 | 29 | 0.100 |
Why?
| | Haplotypes | 4 | 2018 | 490 | 0.100 |
Why?
| | In Situ Hybridization | 3 | 2003 | 319 | 0.100 |
Why?
| | Patch-Clamp Techniques | 2 | 2004 | 289 | 0.100 |
Why?
| | Protein Kinase C | 1 | 2014 | 252 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 983 | 0.090 |
Why?
| | 3' Untranslated Regions | 1 | 2013 | 152 | 0.090 |
Why?
| | In Vitro Techniques | 3 | 2003 | 1047 | 0.090 |
Why?
| | Permeability | 1 | 2012 | 168 | 0.090 |
Why?
| | Dihydro-beta-Erythroidine | 2 | 2010 | 6 | 0.090 |
Why?
| | Rubidium Radioisotopes | 4 | 2004 | 9 | 0.090 |
Why?
| | Statistics as Topic | 1 | 2012 | 284 | 0.090 |
Why?
| | Transfection | 3 | 2013 | 940 | 0.080 |
Why?
| | Gene Frequency | 2 | 2009 | 481 | 0.080 |
Why?
| | Food Preferences | 1 | 2012 | 126 | 0.080 |
Why?
| | Alcoholism | 3 | 2008 | 817 | 0.080 |
Why?
| | Myocardial Infarction | 1 | 2018 | 1209 | 0.080 |
Why?
| | Iodine Radioisotopes | 2 | 2009 | 136 | 0.080 |
Why?
| | Data Interpretation, Statistical | 1 | 2012 | 372 | 0.080 |
Why?
| | Amino Acid Sequence | 3 | 2004 | 2155 | 0.080 |
Why?
| | Decamethonium Compounds | 1 | 2010 | 1 | 0.080 |
Why?
| | Hexamethonium | 1 | 2010 | 5 | 0.080 |
Why?
| | Mecamylamine | 1 | 2010 | 6 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 851 | 0.080 |
Why?
| | Xenopus laevis | 1 | 2010 | 105 | 0.080 |
Why?
| | Genetic Association Studies | 3 | 2018 | 372 | 0.080 |
Why?
| | Electrophysiology | 1 | 2010 | 218 | 0.080 |
Why?
| | Animals, Newborn | 1 | 2012 | 902 | 0.080 |
Why?
| | Organ Specificity | 1 | 2010 | 312 | 0.070 |
Why?
| | Dithiothreitol | 2 | 1988 | 19 | 0.070 |
Why?
| | Rats | 5 | 2013 | 5597 | 0.070 |
Why?
| | Risk | 3 | 2019 | 911 | 0.070 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2008 | 39 | 0.070 |
Why?
| | Luciferases | 3 | 2013 | 152 | 0.070 |
Why?
| | Columbidae | 1 | 2007 | 31 | 0.070 |
Why?
| | Cells, Cultured | 3 | 2025 | 4154 | 0.070 |
Why?
| | Europe | 2 | 2022 | 412 | 0.070 |
Why?
| | Epilepsy | 2 | 2012 | 376 | 0.060 |
Why?
| | Mice, Congenic | 1 | 2006 | 23 | 0.060 |
Why?
| | Lod Score | 1 | 2006 | 62 | 0.060 |
Why?
| | Cocaine-Related Disorders | 1 | 2008 | 132 | 0.060 |
Why?
| | RNA, Messenger | 4 | 2015 | 2832 | 0.060 |
Why?
| | Drug Interactions | 2 | 2004 | 398 | 0.060 |
Why?
| | RNA | 2 | 2010 | 940 | 0.060 |
Why?
| | Drinking Behavior | 1 | 2005 | 13 | 0.060 |
Why?
| | Cadmium Chloride | 1 | 2004 | 4 | 0.060 |
Why?
| | Age of Onset | 2 | 2020 | 551 | 0.060 |
Why?
| | Macrocyclic Compounds | 1 | 2004 | 13 | 0.060 |
Why?
| | Ryanodine | 1 | 2004 | 15 | 0.060 |
Why?
| | Thalamus | 2 | 2009 | 125 | 0.050 |
Why?
| | Reflex, Startle | 5 | 2017 | 76 | 0.050 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 124 | 0.050 |
Why?
| | Inhibitory Concentration 50 | 1 | 2004 | 91 | 0.050 |
Why?
| | Oxazoles | 1 | 2004 | 48 | 0.050 |
Why?
| | Snails | 1 | 2004 | 37 | 0.050 |
Why?
| | Age Factors | 1 | 2012 | 3333 | 0.050 |
Why?
| | Binding, Competitive | 3 | 2003 | 193 | 0.050 |
Why?
| | Extracellular Space | 1 | 2004 | 120 | 0.050 |
Why?
| | Algorithms | 1 | 2012 | 1837 | 0.050 |
Why?
| | Menthol | 1 | 2024 | 12 | 0.050 |
Why?
| | Adult | 12 | 2016 | 40449 | 0.050 |
Why?
| | Membrane Potentials | 1 | 2004 | 280 | 0.050 |
Why?
| | Injections, Intraperitoneal | 2 | 2001 | 116 | 0.050 |
Why?
| | Mice, 129 Strain | 2 | 2015 | 86 | 0.050 |
Why?
| | Sequence Analysis | 1 | 2003 | 35 | 0.050 |
Why?
| | Threonine | 1 | 2003 | 46 | 0.050 |
Why?
| | Electroporation | 1 | 2003 | 41 | 0.050 |
Why?
| | Risk Factors | 5 | 2022 | 10779 | 0.050 |
Why?
| | Tobacco Smoking | 1 | 2023 | 26 | 0.050 |
Why?
| | Sequence Alignment | 1 | 2003 | 366 | 0.050 |
Why?
| | Middle Aged | 9 | 2019 | 35875 | 0.050 |
Why?
| | Alanine | 1 | 2003 | 171 | 0.050 |
Why?
| | Luminescent Proteins | 1 | 2003 | 185 | 0.050 |
Why?
| | Sample Size | 1 | 2022 | 123 | 0.050 |
Why?
| | Suprachiasmatic Nucleus | 1 | 2022 | 19 | 0.050 |
Why?
| | Exons | 1 | 2003 | 358 | 0.050 |
Why?
| | Green Fluorescent Proteins | 1 | 2003 | 405 | 0.040 |
Why?
| | DNA | 3 | 2010 | 1463 | 0.040 |
Why?
| | Synaptic Transmission | 1 | 2024 | 290 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3409 | 0.040 |
Why?
| | Biological Transport, Active | 1 | 2001 | 69 | 0.040 |
Why?
| | Genetic Loci | 1 | 2022 | 261 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 824 | 0.040 |
Why?
| | Serum Albumin, Bovine | 1 | 2001 | 62 | 0.040 |
Why?
| | Blotting, Western | 1 | 2003 | 1187 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2001 | 276 | 0.040 |
Why?
| | Interneurons | 1 | 2001 | 128 | 0.040 |
Why?
| | Injections, Intraventricular | 1 | 2000 | 56 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2023 | 318 | 0.040 |
Why?
| | Molecular Sequence Data | 2 | 2004 | 2930 | 0.040 |
Why?
| | Adolescent | 7 | 2019 | 22428 | 0.040 |
Why?
| | Odds Ratio | 2 | 2016 | 1075 | 0.040 |
Why?
| | Blotting, Southern | 1 | 2000 | 85 | 0.040 |
Why?
| | Models, Biological | 1 | 2008 | 1821 | 0.040 |
Why?
| | Hybridization, Genetic | 1 | 2000 | 74 | 0.040 |
Why?
| | Hyperkinesis | 1 | 2019 | 16 | 0.040 |
Why?
| | Feeding Behavior | 1 | 2005 | 684 | 0.040 |
Why?
| | Methylphenidate | 1 | 2019 | 49 | 0.040 |
Why?
| | Gene Transfer Techniques | 1 | 2000 | 185 | 0.040 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2019 | 59 | 0.040 |
Why?
| | Cattle | 1 | 2001 | 1000 | 0.040 |
Why?
| | Protective Factors | 1 | 2018 | 99 | 0.030 |
Why?
| | Linkage Disequilibrium | 2 | 2009 | 246 | 0.030 |
Why?
| | Autophagosomes | 1 | 2017 | 20 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 1999 | 1253 | 0.030 |
Why?
| | Protein Binding | 1 | 2003 | 2273 | 0.030 |
Why?
| | Prepulse Inhibition | 1 | 2017 | 12 | 0.030 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2017 | 35 | 0.030 |
Why?
| | Inflammasomes | 1 | 2018 | 146 | 0.030 |
Why?
| | Kinetics | 4 | 2004 | 1627 | 0.030 |
Why?
| | Radioimmunoassay | 1 | 1996 | 165 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2015 | 3540 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2018 | 395 | 0.030 |
Why?
| | Young Adult | 4 | 2016 | 14105 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2017 | 370 | 0.030 |
Why?
| | Binding Sites | 3 | 2007 | 1329 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2009 | 2637 | 0.030 |
Why?
| | Chromosomes, Human, Pair 15 | 1 | 2015 | 50 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2018 | 509 | 0.030 |
Why?
| | CRISPR-Cas Systems | 1 | 2017 | 170 | 0.030 |
Why?
| | Autophagy | 1 | 2017 | 286 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2017 | 389 | 0.030 |
Why?
| | DNA Primers | 2 | 2008 | 512 | 0.030 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2019 | 428 | 0.030 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 920 | 0.030 |
Why?
| | Transcription Factors | 1 | 2022 | 1741 | 0.030 |
Why?
| | Mice, Inbred AKR | 2 | 2003 | 37 | 0.030 |
Why?
| | Mice, Inbred A | 2 | 2003 | 48 | 0.030 |
Why?
| | NF-kappa B | 1 | 2017 | 661 | 0.030 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2013 | 87 | 0.020 |
Why?
| | Down-Regulation | 1 | 2015 | 627 | 0.020 |
Why?
| | Cell Movement | 1 | 2017 | 965 | 0.020 |
Why?
| | Lactation | 1 | 2014 | 192 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2008 | 1054 | 0.020 |
Why?
| | Adolescent Development | 1 | 2012 | 72 | 0.020 |
Why?
| | Case-Control Studies | 2 | 2010 | 3604 | 0.020 |
Why?
| | Aged | 3 | 2018 | 25913 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2015 | 8265 | 0.020 |
Why?
| | Macrophages | 1 | 2018 | 1511 | 0.020 |
Why?
| | Inflammation | 1 | 2021 | 2878 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4564 | 0.020 |
Why?
| | Respiration | 3 | 2002 | 206 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2014 | 576 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4282 | 0.020 |
Why?
| | Ligands | 2 | 2003 | 673 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 379 | 0.020 |
Why?
| | Dizziness | 1 | 2010 | 101 | 0.020 |
Why?
| | Receptors, Muscarinic | 1 | 1989 | 20 | 0.020 |
Why?
| | Autistic Disorder | 1 | 2012 | 211 | 0.020 |
Why?
| | Heart Rate | 4 | 2002 | 855 | 0.020 |
Why?
| | Alkylation | 1 | 1988 | 27 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 1989 | 172 | 0.020 |
Why?
| | Disulfides | 1 | 1988 | 96 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2008 | 333 | 0.020 |
Why?
| | Receptors, Opioid | 1 | 1987 | 23 | 0.020 |
Why?
| | Administration, Cutaneous | 1 | 2007 | 125 | 0.020 |
Why?
| | Family Health | 1 | 2008 | 191 | 0.020 |
Why?
| | Gene Deletion | 1 | 2009 | 389 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 529 | 0.020 |
Why?
| | MicroRNAs | 1 | 2013 | 701 | 0.020 |
Why?
| | Smoking Prevention | 1 | 2007 | 166 | 0.020 |
Why?
| | Nucleus Accumbens | 1 | 2007 | 132 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2010 | 1326 | 0.010 |
Why?
| | Prospective Studies | 1 | 2018 | 7990 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2013 | 2050 | 0.010 |
Why?
| | Logistic Models | 1 | 2010 | 2117 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2008 | 1539 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2925 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 1988 | 1087 | 0.010 |
Why?
| | Receptors, Neurotransmitter | 1 | 2003 | 20 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2004 | 540 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2015 | 6429 | 0.010 |
Why?
| | Smoking Cessation | 1 | 2007 | 439 | 0.010 |
Why?
| | Substantia Nigra | 1 | 2003 | 63 | 0.010 |
Why?
| | Mice, Mutant Strains | 1 | 2003 | 299 | 0.010 |
Why?
| | Genomics | 1 | 2008 | 834 | 0.010 |
Why?
| | Drug Tolerance | 3 | 1987 | 100 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2004 | 675 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1370 | 0.010 |
Why?
| | Cell Count | 1 | 2001 | 320 | 0.010 |
Why?
| | Infant | 1 | 2015 | 10034 | 0.010 |
Why?
| | Veratridine | 1 | 2000 | 5 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 2000 | 53 | 0.010 |
Why?
| | Drug Resistance | 1 | 2001 | 153 | 0.010 |
Why?
| | Hypothermia | 1 | 2001 | 52 | 0.010 |
Why?
| | United States | 1 | 2018 | 15966 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 2001 | 205 | 0.010 |
Why?
| | Child, Preschool | 1 | 2015 | 11787 | 0.010 |
Why?
| | Potassium | 1 | 2000 | 152 | 0.010 |
Why?
| | Disease Susceptibility | 1 | 2001 | 348 | 0.010 |
Why?
| | Genetic Testing | 1 | 2001 | 478 | 0.010 |
Why?
| | Cohort Studies | 1 | 2009 | 5960 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2001 | 1716 | 0.010 |
Why?
| | Child | 1 | 2015 | 22633 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2007 | 11679 | 0.010 |
Why?
| | Quinuclidinyl Benzilate | 1 | 1989 | 3 | 0.000 |
Why?
| | Dithionitrobenzoic Acid | 1 | 1986 | 3 | 0.000 |
Why?
| | Rats, Inbred Strains | 1 | 1986 | 321 | 0.000 |
Why?
| | Infusions, Intravenous | 1 | 1987 | 423 | 0.000 |
Why?
| | Peptide Hydrolases | 1 | 1986 | 105 | 0.000 |
Why?
| | Hot Temperature | 1 | 1986 | 407 | 0.000 |
Why?
| | Oxygen Consumption | 1 | 1986 | 724 | 0.000 |
Why?
|
|
Stitzel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|